title: Advances in Heart Failure Management: Improving Outcomes With Innovation.
abstract: Heart failure (HF) is a chronic and complex disease entity with an enormous morbidity and mortality. Many of the therapies used in the management of HF were developed decades ago, but recently more novel monitoring and therapeutic strategies have emerged. The employment of these strategies may reduce morbidity and mortality in patients with HF. This article reviews the epidemiology of HF and some of the novel strategies developed to assess risk and monitor these challenging patients. It also discusses the evidence behind some of the newer treatments available that are recently included in the HF management guidelines. Various devices used in the treatment of HF, some of which remain investigational, are also discussed. Novel strategies for remote monitoring and new pharmacologic therapies may be useful in improving morbidity and mortality in patients with HF.
authors.affiliation: Cardiology Division, Massachusetts General Hospital, Boston, MA.
authors.forename: Nasrien E
authors.initials: NE
authors.lastname: Ibrahim
authors.affiliation: Cardiology Division, Brigham and Women's Hospital, Boston, MA.
authors.forename: Akshay S
authors.initials: AS
authors.lastname: Desai
authors.affiliation: Cardiology Division, Massachusetts General Hospital, Boston, MA.
authors.forename: Jagmeet P
authors.initials: JP
authors.lastname: Singh
authors.affiliation: Cardiology Division, Massachusetts General Hospital, Boston, MA; Institute for Clinical Research, Boston, MA.
authors.forename: James L
authors.initials: JL
authors.lastname: Januzzi
mesh_terms: D006328:Cardiac Catheterization / Q000009:adverse effects / Q000401:mortality; D058406:Cardiac Resynchronization Therapy / Q000009:adverse effects / Q000401:mortality; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004059:Diffusion of Innovation; D006333:Heart Failure / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D020127:Recovery of Function; D012307:Risk Factors; D004561:Transcutaneous Electric Nerve Stimulation / Q000009:adverse effects / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents